期刊文献+

抗革兰阳性细菌药物研究进展 被引量:6

Progress on reseach of anti-gram positive bacteria drugs
在线阅读 下载PDF
导出
摘要 近20多年来,革兰阳性菌的感染和耐药日益增加,正在成为威胁人类健康的重大临床难题,人们需要寻求更有效的抗菌药物。近年来新的抗革兰阳性菌感染药物取得了不少进展,如新的糖肽类、链阳霉素类、脂肽类、恶唑烷酮类、新一代氟喹诺酮类等药物不断问世,为人类与细菌的斗争提供了有力的武器。 Increasing infectious rate and drug resistance of gram positive bacteria have become a serious problem threatening the health of human beings in recent 20 years. More effective antibiotic drugs are needed with arousing creation of new drugs accompanied by advances in production of more sophisiticated ones, such as new glycopeptides, streptogramins, lipopeptides, oxazolidinones, new generation of fluoroquinolones and so on, providing powerful weapons to fight against bacterias.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第7期543-548,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 革兰阳性菌 抗菌药 药物疗法 gram positive bacteria anti-bacterial agents drug therapy
作者简介 陆菲婕(1983-),女,浙江宁波人,在读硕士研究生,主要从事细菌感染研究。 【通讯作者】徐志豪。Phn:86—571—8778—3552;86—13600516684。E—mail:zhihaox@sina.com
  • 相关文献

参考文献42

  • 1DIEKEMA DJ, PFALLER MA, SCHMITZ FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997 - 1999[J]. Clin Infect Dis, 2001,32 Suppl 2: S114- S132.
  • 2王辉,孙宏莉,陈民钧,胡必杰,俞云松,孙自庸,褚云卓,徐英春,谢秀丽.2005年我国五家教学医院革兰阳性球菌耐药监测研究[J].中华检验医学杂志,2006,29(10):873-877. 被引量:120
  • 3梁声强,张阳根,江先海.肺部感染细菌的分离培养及耐药情况分析[J].实用医技杂志,2006,13(18):3189-3190. 被引量:1
  • 4汪复.抗菌药物临床应用进展[J].中国抗感染化疗杂志,2002,2(2):115-119. 被引量:39
  • 5ALLEN NE, NICAS TI. Mechanism of action of oritavancin and related glycopeptide antibiotics[J]. FEMS Microbiol Rev, 2003, 26(5):511 - 532.
  • 6PATEL R, ROUSE MS, PIPER KE, et al. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin- resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae [J]. Diagn Microbiol Infect Dis, 1998, 30(2): 89 - 92.
  • 7van BAMBEKE F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy[J]. Curr Opin Investig Drugs, 2006, 7 (8) : 740-749.
  • 8CITRON DM, KWOK YY, APPLEMAN MD, In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens , Propionlbacterium aches , and anaerobic Gram-positive cocci[J]. Anaerobe, 2005, 11 (1-2) : 93 - 95.
  • 9COREY GR, STRYJEWSKI ME, O'RIORDAN WD, et al. ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections [J]. Clin Microb Infect, 2007, 29 Suppl 2: S216- S217.
  • 10COREY GR, STRYJEWSKI ME, FOWLER VG, et al. ATLAS 2: a double-blind, randomised, active controlled, multinational Phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections[J]. Clin Microb Infect, 2007, 29 Suppl 2: S217.

二级参考文献53

共引文献195

同被引文献41

引证文献6

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部